Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Long-Term Investments: 2017-2025

Historic Long-Term Investments for Aclaris Therapeutics (ACRS) over the last 5 years, with Sep 2025 value amounting to $71.3 million.

  • Aclaris Therapeutics' Long-Term Investments rose 55.96% to $71.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year increase of 55.96%. This contributed to the annual value of $90.3 million for FY2024, which is 43.86% up from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Long-Term Investments is $71.3 million, which was down 12.07% from $81.1 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Long-Term Investments registered a high of $91.0 million during Q2 2023, and its lowest value of $7.2 million during Q2 2022.
  • Over the past 3 years, Aclaris Therapeutics' median Long-Term Investments value was $71.3 million (recorded in 2025), while the average stood at $65.2 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Long-Term Investments slumped by 79.07% in 2022 and then surged by 1,160.10% in 2023.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Long-Term Investments stood at $34.2 million in 2021, then slumped by 64.25% to $12.2 million in 2022, then surged by 412.75% to $62.8 million in 2023, then surged by 43.86% to $90.3 million in 2024, then soared by 55.96% to $71.3 million in 2025.
  • Its last three reported values are $71.3 million in Q3 2025, $81.1 million for Q2 2025, and $85.2 million during Q1 2025.